CBS 2019
CBSMD教育中心
中 文

动脉粥样硬化性心血管疾病预防

Abstract

Recommended Article

Short-Term Progression of Multiterritorial Subclinical Atherosclerosis Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes High-Risk Coronary Plaque Regression After Intensive Lifestyle Intervention in Nonbstructive Coronary Disease: A Randomized Study Primary Prevention Trial Designs Using Coronary Imaging: A National Heart, Lung, and Blood Institute Workshop Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial Negative Risk Markers for Cardiovascular Events in the Elderly Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Original Research2021 Mar 25;cvab100.

JOURNAL:Cardiovasc Res. Article Link

Treatment and prevention of lipoprotein(a)-mediated cardiovascular disease: the emerging potential of RNA interference therapeutics

DI Swerdlow, DA Rider, A Yavari et al. Keywords: lipoprotein(a)-mediated cardiovascular disease; treatment option; RNA interference therapeutics

Full Text PDF